Iran Press/ Asia: The vaccine candidate jointly developed by CanSino Biological Inc and Beijing Institute of Biotechnology uses the non-replicating viral vector as the platform, same as the non-Corona candidates like Ebola, to develop a vaccine with a 'Adenovirus Type 5' candidate, a draft landscape of COVID-19 vaccine candidates brought out today, the " businesstoday" reported.
Sources say adenoviruses are common viruses that cause pneumonia and can deliver potential antigens to stimulate the production of antibodies that work against the disease. CanSino Biological Inc, in association with the Chinese Academy of Military Medical Science's Bioengineering Institute, had developed an Ebola vaccine in 2017.
The other vaccine that has entered the first phase of trials is from the US-based biotech firm Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) combine. This lipid nanoparticle (LNP) encapsulated mRNA candidate vaccine uses an RNA platform with multiple candidates.
In this vaccine, the virus's genetic information is de-coded from the DNA to make proteins. mRNA, or messenger RNA, acts as an intermediary between the genetic information in DNA and the amino acid sequence of proteins, which gives cells command to make proteins that fight the viruses. But such vaccines have not yet been approved for human use, said sources.
Earlier, it was reported that India's Zydus Cadila, Serum Institute and Bharat Biotech are among the global firms working on COVID-19 vaccine.
The WHO update says 60 vaccine candidates are in the pre-clinical trial stage. Experts believe it will take 12 to 18 months before a vaccine is available.
Normally, the vaccine candidate, from the pre-clinical stage, which includes testing in small and large animals, have to go through three phases of clinical trials to prove its safety and efficacy.
These human trials are done on different population in various geographies and have to create huge data in the 3 phases of human trials for regulatory sanctions. In emergencies like this, fast tracking is possible, but the vaccine candidates still have to go through various trials before being introduced in the market.
Typically, only one in ten experimental vaccines make it all the way through to regulatory approval.
Earlier on Mar 16, The United States was reportedly preparing to start a clinical trial of a new vaccine, which has not been announced publicly and developed to protect against the coronavirus (COVID-19) pandemic.
The trial had not been announced publicly but the official reportedly said that participants will receive an experimental vaccine at the Kaiser Permanente Washington Health Research Institute in Seattle, the Associated Press reported, citing an unnamed US administration official. 212/ 104
Read More:
US to begin clinical trial of possible Coronavirus Vaccine
Rouhani: All efforts must be exerted for building anti-corona vaccine, drug
